Ottawa – Chairperson of the Patented Medicine Prices Review Board (PMPRB), Mr. Thomas Digby has stepped down from his role, effective March 6, 2025, to pursue other opportunities. The PMPRB’s Vice-Chairperson, Anie Perrault, has assumed the duties of acting Chairperson until a permanent replacement for Digby is appointed by the Governor in Council. Digby was appointed as Chairperson during a …
Ottawa – The Patented Medicine Prices Review Board has published its latest report, Private Drug Plans in Canada: Expenditure Report, 2018–2023. This report provides insight into the factors driving growth in prescription drug costs for private drug plans in 2023, as well as a retrospective review of trends in private drug plan costs and utilization since 2018. As key stakeholders in the …
Ottawa – Mark Holland, Federal Minister of Health, today tabled the 2023 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the Senate and the House of Commons. The 2023 Annual Report outlines trends in the prices and sales of patented medicines in Canada. Sales of patented medicines in 2023 were $19.9 billion and accounted …
Ottawa – Mark Holland, Minister of Health, announced a new appointment to the Patented Medicine Prices Review Board (PMPRB). Following a merit-based selection process, Sharon Blady is appointed to the Board for a five-year term. The Government of Canada is committed to appointing highly-qualified candidates to best serve the interests of Canadians and is committed to open, transparent, and merit-based processes …
Ottawa – The Patented Medicine Prices Review Board (PMPRB) has published its What We Learned Report, which summarizes the feedback received in the Policy Roundtable meetings it hosted in December. The report, along with the written submissions received, will help inform the PMPRB’s next steps toward developing new Guidelines. The What We Learned Report is a summary of the opinions …
Ottawa – The Patented Medicine Prices Review Board (PMPRB) has published its What We Learned Report, which summarizes the feedback received in the Policy Roundtable meetings it hosted in December. The report, along with the written submissions received, will help inform the PMPRB’s next steps toward developing new Guidelines. The What We Learned Report is a summary of the opinions …
Ottawa – The latest edition of the Patented Medicine Prices Review Board (PMPRB) CompassRx report shows that the 10 highest-cost drugs reimbursed by public drug plans in Canada were all rare disease treatments with annual treatment costs of over $250,000. CompassRx is an annual report published under the National Prescription Drug Utilization Information System (NPDUIS) research initiative. CompassRx provides insight into the factors driving prescription …
Ottawa – The Patented Medicine Prices Review Board (PMPRB) will launch the first phase of consultations on its new Guidelines by inviting stakeholders to participate in a Policy Roundtable on December 5 (English session) and December 6 (French session). The intent of this phase is to foster a productive conversation, where all parties can voice their opinions and concerns. At …
Ottawa – The Patented Medicine Prices Review Board (PMPRB) published today the 7th edition of its annual Meds Entry Watch report. The analysis finds that the number of new medicines launched in Canada is higher than the median for Organisation for Economic Co-operation and Development (OECD) countries but falls below the median of the eleven PMPRB comparators, all of which have lower average …
Ottawa – Mark Holland, Minister of Health, announced a new appointment to the Patented Medicine Prices Review Board (PMPRB). Following a merit-based selection process, Anie Perrault is appointed as Vice Chairperson for a five-year term. With over 30 years of experience in the public and private sectors, Ms. Perrault held several positions in the genomic research and biotechnology sector both in Quebec …
